Ligand Pharmaceuticals, Inc. (LGND)
$2.11
0.01 (+0.48%)
| CAPS Rating |
|
|---|---|
| Open | $2.18 |
| Previous Close | $2.10 |
| Daily Range | $2.04 - $2.23 |
| 52-Week Range | $1.22 - $3.21 |
| Market Cap | $238.46M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 355,372 |
| Average Daily Volume | 425,000 |
LGND
VS S&P 500 (SPY)
How do you think LGND will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
LGND Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
LGND News and Commentary
- DARA—Time to Harvest – Blog at The Motley Fool
- 4-Star Stocks on the Upswing – The Motley Fool
- Pharma's Next Home Run Drug Could Be 4 Singles Instead – The Motley Fool
- 4-Star Stocks on the Upswing – The Motley Fool
- 4-Star Stocks on the Upswing – The Motley Fool
- 5 Cold Stocks Heating Up – The Motley Fool
- 3 Stocks Ready to Roar – The Motley Fool
- The FDA Leaves Pfizer in the Waiting Room – The Motley Fool
- Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink – The Motley Fool
- Making Cents in Penny Stocks – The Motley Fool
- Small cap biotech: The GOOD (part II) – Blog at The Motley Fool
- Is Amgen's Nplate a Blockbuster? – The Motley Fool
- Emerging Biotech & Pharma Index: 36 More Cos. – Blog at The Motley Fool
- Ligand and Glaxo Like the FDA's Answer – The Motley Fool
- Ugly lessons in biotech: Avoid binary events – Blog at The Motley Fool
- Unloved Stocks Ready to Shine – The Motley Fool
- Will These Delayed Drugs Make It to Market? – The Motley Fool
- Amgen's Back – The Motley Fool
- A Pfizer Drug With a Cloudy Future – The Motley Fool
- Amgen Gets Its FDA Response – The Motley Fool
RSS Headlines
Fool UK
